August 25, 2011 – Two articles in the Society of Interventional Radiology (SIR)'s flagship publication, the Journal of Vascular and Interventional Radiology, report on studies related to peripheral arterial disease (PAD), coinciding with the approach of September's National PAD Awareness Month.

August 25, 2011 – The U.S. Food and Drug Administration (FDA) has released its list of pre-market approval (PMA) and 510(k) decisions for new or enhanced medical devices from June 2011. The list includes all FDA PMAs, product development protocols (PDP), supplement and notice decisions. This list is generated on a monthly basis.

August 24, 2011 -- Radiopharmaceuticals are pharmaceutical agents used to diagnose certain medical problems, such as cardiac, cancer or neurology, and/or treat certain conditions such as cancers. The use of radiopharmaceuticals as tracer dates back to 1930s.

August 24, 2011 — Cleveland HeartLab Inc. (CHL), a specialty clinical laboratory and disease management company, announced the completion of an $18.4-million Series B financing round. The rapidly growing company hopes to further accelerate market adoption of its advanced approach to assessing cardiovascular disease risk using biomarkers of inflammation. This approach includes the company’s CardioMPO test for circulating myeloperoxidase, the anchor of its proprietary inflammation panel.

August 23, 2011 — A new study shows heart attack patients are now being treated an average of 32 minutes faster than five years ago. This provides evidence a national campaign's success to treat heart attacks within 90 minutes in order to reduce heart damage and costs associated with treatment. This is according to David Holmes, M.D., FACC, president of the American College of Cardiology (ACC).

August 23, 2011 — nContact Inc. has received CE Mark approval for the EPi-Sense Guided Coagulation Device with VisiTrax for the treatment of cardiac arrhythmias, including atrial fibrillation (AF). The EPi-Sense features epicardial sensing electrodes designed to allow both electrophysiologists (EP) and cardiothoracic surgeons to map and navigate the epicardium and locate areas for linear epicardial ablation.

August 23, 2011 — Cardium Therapeutics received the final $1.1 million payment from Royal Philips Electronics in connection with Philips' acquisition of Innercool Therapies from Cardium. The purchase gives Philips Healthcare a therapeutic hypothermia product line for use in heart attack, sudden cardiac arrest and neuro trauma patients